Last updated on July 2018

Phase I/II Study of SAR422459 in Patients With Stargardt's Macular Degeneration


Brief description of study

Primary Objective:

To assess the safety and tolerability of ascending doses of SAR422459 in patients with Stargardt's Macular Degeneration.

Secondary Objective:

To evaluate for possible biological activity of SAR422459.

Detailed Study Description

The total duration per patient is up to 52 weeks, which includes a 4 week screening period and a 48 weeks study period.

At the end of the study, the patient will be invited to enter in an open-label safety study (LTS13588) and long-term follow-up visits including ophthalmological examinations and recording of adverse events for up to 15 years.

Clinical Study Identifier: NCT01367444

Contact Investigators or Research Sites near you

Start Over

Trial Transparency email recommended (Toll ...

Investigational Site Number 840002
Miami, FL United States
  Connect »

Trial Transparency email recommended (Toll ...

Investigational Site Number 840005
Iowa City, IA United States
  Connect »

Trial Transparency email recommended (Toll ...

Investigational Site Number 840001
Portland, OR United States
  Connect »

Trial Transparency email recommended (Toll ...

Investigational Site Number 840004
Houston, TX United States
  Connect »

Trial Transparency email recommended (Toll ...

Investigational Site Number 250001
Paris, France
  Connect »